恶性胸膜间皮瘤免疫检查点抑制剂的研究进展

Research Progress of Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma

恶性胸膜间皮瘤(malignant pleural mesothelioma,MPM)是一种侵袭性强、生存率低且缺乏有效治疗选择的恶性肿瘤。培美曲塞联合顺铂作为晚期MPM唯一的一线治疗方案长达20年之久。长期以来,免疫疗法被认为是MPM的一种潜在治疗方法,主要包括免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)、免疫毒素治疗、抗癌疫苗、过继性细胞治疗等。本篇综述重点总结了MPM中ICIs的研究进展,初步分析了MPM肿瘤异质性对ICIs治疗的影响,描述了以生物标志物为导向的免疫治疗是实现MPM个体化治疗的新愿景。

Malignant pleural mesothelioma(MPM)is a malignant tumor with strong invasiveness,low survival rate and lack of effective treatment options.As the only first-line treatment plan for the advanced MPM,combination of pemetrexed and cisplatin chemotherapy have been existing since the last 20 years.Immunotherapy has long been considered as a potential treatment plan for MPM,mainly including immune checkpoint inhibitors(ICIs),immunotoxin therapy,anti-cancer vaccine and adoptive T-cell therapy.This review focuses on summarizing the current research status of immune checkpoint inhibitors in MPM,discusses the effect of tumor heterogeneity on ICIs treatment,and describes that the biomarker-oriented immunotherapy is a new vision for the realization of individualized treatment of MPM.